Dr. Albert Grinshpun completed his M.D. at the Hebrew University in Jerusalem, Israel in 2010. During his M.D. he also completed M.Sc. in gene therapy. Then, he went on and completed his service in the Israel Defense Forces, followed by a residency in Medical Oncology at the Sharett Institute of Oncology of the Hadassah-Hebrew University Medical Center, Jerusalem.

During training, Albert accomplished a basic research fellowship at the Weizmann Institute where he investigated tumor microbiome. Notably, while being a resident, Albert won several highly prestigious competitive grants including the Ministry of Science Personalized Medicine grant, Physician-Scientist award from the Israel Science Foundation (ISF), and the Conquer Cancer (ASCO)-Israel Cancer Research Fund Career Development Award.

After completion of his training, Dr. Grinshpun joined the international Goldfarb Advanced Fellowship program in Medical Oncology at Dana-Farber/Harvard Cancer Center in Boston. Albert studied mechanisms of endocrine resistance in metastatic hormone receptor-positive breast cancer and ctDNA studies, mentored by Drs. Lin and Jeselsohn of Dana-Farber. In parallel, Albert was involved in translational research, clinical trial design and multidisciplinary patient care.

Dr. Grinshpun has published more than 40 peer reviewed original articles. Among these publications are manuscripts published in Annals of Oncology and JAMA Oncology.

In August 2023 Albert returned to Israel and currently he’s leading the Breast Oncology Service at Shaare Zedek Medical Center, Jerusalem. In addition, Albert is leading a research team focused on Women’s cancers, affiliated to the Hebrew University of Jerusalem.